CEO SUMMARY: In a call to action, the National Independent Laboratory Association is urging lab owners, lab managers, and pathologists to educate their members of Congress about the biases and deep flaws built into the final rule for PAMA market price reporting and how the rule will result in reduced access to clinical lab testing
Tag: laboratory manager
CEO SUMMARY: Only a few months remain before the federal Centers for Medicare and Medicaid Services makes deep price cuts to Medicare Part B clinical laboratory test fees. Before those cuts go into effect, lab associations and lab professionals are educating members of Congress and the new administration about the bias and flaws in CMS’
CEO SUMMARY: In Dallas, the relatively short-lived lab company known as Med Fusion has a new owner. After seven years, the lab partnership of Baylor Scott and White, US Oncology Network, Texas Oncology, and Pathologists Bio-Medical Laboratories decided to sell their ownership stakes to Quest Diagnostics. The sale comes despite $100 million of capital and
TO MAKE THE TRANSITION FROM VOLUME TO VALUE, pathologists and clinical laboratory scientists are beginning to leave the four walls of their labs to engage clinicians in ways that add value to the lab tests performed on their patients.
That’s exactly what one medical technologist is doing in a community hospital in the Midwest. Daily, she
IT IS ALWAYS INSPIRING TO LEARN THE STORIES OF CLINICAL LABORATORY SCIENTISTS who spot opportunities to improve patient care, then take initiative to seize that opportunity and help patients get better. Such is the case of a medical technologist in a 25-bed rural hospital who now participates in daily rounds.
Christina L. Bard, CLS(ASCP), MBA, is
CEO SUMMARY: Transparency tools, such as those from Castlight Health, help consumers see the significant variation in clinical laboratory test prices. In this analysis, THE DARK REPORT argues that lab executives and pathologists should recognize how two factors are poised to change the status quo in how labs price their tests. One is the credibility
CEO SUMMARY: It’s a case of the little fish gobbling the big fish, as Opko Health—with revenue of $91 million—will be acquiring Bio-Reference Laboratories, with revenue of $832 million. But the more interesting aspect of the story is that the CEO of Opko Health is a physician worth $5 billion and highly respected by Wall Street. It could be that Bio-Reference CEO Marc Grodman, M.D., has gained a shrewd advisor and powerful ally in Phillip Frost, M.D., the Chair and CEO of Opko Health.
CEO SUMMARY: In coming years, there will be multiple challenges and opportunities for the nation’s clinical laboratories and pathology groups. That was one common theme heard from the 90 speakers and panelists at the 19th annual Executive War College on Laboratory and Pathology Management that took place on April 29-30 in New Orleans. Lab managers
CEO SUMMARY: Probably no state has seen a faster transition to ACOs, medical homes, and other types of integrated clinical care organizations than Arizona. Recognizing that this change created a new opportunity to add more value with clinical lab testing services, Sonora Quest Laboratories (SQL) developed an enterprise-wide master patient index. This gives SQL the
CEO SUMMARY: One trend getting little publicity is that of health information exchanges (HIEs). Since its founding in 2009, the Colorado Regional Health Information Organization (CORHIO) has grown steadily. Today, most of the state’s independent lab companies and hospital laboratories are connected to CORHIO. Real-time access to laboratory test data is one feature that has